Influence of diabetes on survival of patients with glioma: a meta-analysis.

2026-02-12
Frontiers in endocrinology 17
- Jing Yi
- Jiangli Wen
- Nianhua Wang
- Min Yuan
- Haibin Leng
- Hua Chen

PubMed: 41767392
DOI: 10.3389/fendo.2026.1667242

Study Design

Type: Meta-Analysis
Sample size: n = 948
Population: patients with glioma (12 retrospective cohort studies comprising 8,948 patients)
Methods: systematically searched PubMed, Embase, and Web of Science up to April 30, 2025, for cohort studies reporting hazard ratios; random-effects model used to pool multivariate-adjusted HRs

Background

The prognostic impact of preexisting diabetes on glioma survival remains unclear, with conflicting evidence across studies. This meta-analysis aimed to assess the association between diabetes and survival outcomes in patients with glioma.

Methods

We systematically searched PubMed, Embase, and Web of Science up to April 30, 2025, for cohort studies reporting hazard ratios (HRs) for overall survival (OS) or progression-free survival (PFS) in glioma patients with and without preexisting diabetes. A random-effects model was used to pool multivariate-adjusted HRs accounting for the possible influence of heterogeneity.

Results

Twelve retrospective cohort studies comprising 8,948 patients were included. Eleven studies reported on OS, and four on PFS. Pooled analysis showed that preexisting diabetes was associated with poorer OS (HR: 1.22, 95% CI: 1.10-1.36, p < 0.001; I² = 33%). Sensitivity analysis confirmed result robustness (HR range: 1.18-1.26). Subgroup analyses revealed consistent associations regardless of tumor grade (Grade III-IV: HR: 1.42; GBM: HR: 1.19; p for subgroup difference = 0.47), age (< 60 vs. ≥ 60 years, p = 0.15), sex distribution (< 60% vs. ≥ 60% men, p = 0.91), diabetes type (type 2 vs. overall diabetes, p = 0.33), or follow-up duration (≤ 12 vs. >12 months, p = 0.69). Preexisting diabetes was also associated with poorer PFS (HR: 1.36, 95% CI: 1.01-1.83, p = 0.04; I² = 0%).

Conclusions

Preexisting diabetes is associated with reduced survival in glioma patients. These findings highlight the importance of integrating metabolic comorbidities into glioma prognostic assessment.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251086248, identifier CRD420251086248.